Iquix (Levofloxacin Ophthalmic) - Summary

IQUIX SUMMARY

IQUIX^®
(levofloxacin ophthalmic solution) 1.5%

IQUIX^® (levofloxacin ophthalmic solution) 1.5% is a sterile topical ophthalmic solution. Levofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of Gram-positive and Gram-negative ocular pathogens. Levofloxacin is a fluorinated 4-quinolone containing a six-member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure. Levofloxacin is the pure(-)-(S)-enantiomer of the racemic drug substance, ofloxacin. It is more soluble in water at neutral pH than ofloxacin.

IQUIX^® solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria:

GRAM-POSITIVE BACTERIA:
*Efficacy for this organism was studied in fewer than 10 infections.
Corynebacterium species*
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae
Viridans group streptococci*
GRAM-NEGATIVE BACTERIA:
Pseudomonas aeruginosa
Serratia marcescens*

IQUIX NEWS HIGHLIGHTS

Published Studies Related to Iquix (Levofloxacin Ophthalmic)

Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial. [2008.03]

A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. [2008.01]

Prospective randomized comparison of 1-day versus 3-day application of topical levofloxacin in eliminating conjunctival flora. [2007.09]

Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. [2007.05]

Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. [2006.12]

more>>

Clinical Trials Related to Iquix (Levofloxacin Ophthalmic)

An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis [Active, not recruiting]

A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects [Completed]

Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis [Completed]

Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections [Completed]

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers [Completed]

more>>